May 31, 2024 06:12 GMT
Sanofi (SANFP: A1 pos / AA): Dupixent Approval
HEALTHCARE
The European Medicines Agency approves Sanofi’s anti-inflammatory Dupixent for COPD.
- Dupixent is Sanofi’s potential blockbuster with Peak Annual Sales hoped to exceed $20b over the decade.
- Sanofi does trade very well already with the 38s 10-12bps inside ROSW & MRK.
38 words